FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
MacroGenics pays for its ASCO exuberance
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
MacroGenics muddies its key catalyst
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
AACR 2024 preview – “cancer vaccines” primed to underwhelm
Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.
Warning signs for Xencor
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
